Extract
Thousands of Italians with COVID-19 were admitted to the hospital. In the Piedmont Region 12 272 patients as of May 12 2020 [1] survived the hospital admission, and most of them were discharged home. As the influx of COVID-19 patients is exceeding the hospital bed-capacity in Northern Italy, patients are discharged home after two negative reverse transcription polymerase chain reaction (RT-PCR) tests for the acute respiratory syndrome (SARS)-CoV-2, notwithstanding their physical status. Nevertheless, lower-limb muscle deconditioning and an impaired performance of activities of daily living (ADLs) are likely to occur. Indeed, COVID-19 patients suffer from multiple symptoms during hospitalisation, and the acute care takes place in strict isolation, which will reduce patient's mobility to zero [2].
Abstract
About half of the post-COVID-19 patients had severe impairments in physical functioning and during the ADLs at discharge home.This current results provide a clear rationale to study the safety and efficacy of rehabilitative interventions in these patients.
Footnotes
Support statement: This work was supported by the Ricerca Corrente Funding scheme of the Ministry of Health, Italy.
Conflict of interest: Dr. Belli has nothing to disclose.
Conflict of interest: Dr. Balbi has nothing to disclose.
Conflict of interest: Dr. Prince has nothing to disclose.
Conflict of interest: Dr. Davide has nothing to disclose.
Conflict of interest: Dr. Masocco has nothing to disclose.
Conflict of interest: Dr. Zaccaria has nothing to disclose.
Conflict of interest: Dr. Bertalli has nothing to disclose.
Conflict of interest: Dr. Cattini has nothing to disclose.
Conflict of interest: Dr. Lomazzo has nothing to disclose.
Conflict of interest: Dr. Dal Negro has nothing to disclose.
Conflict of interest: Dr. Giardini has nothing to disclose.
Conflict of interest: Dr. Franssen reports grants and personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GlaxoSmithKline, grants and personal fees from Novartis, personal fees from TEVA, outside the submitted work;.
Conflict of interest: Dr. Janssen reports personal fees from Astra Zeneca, personal fees from Novartis, personal fees from Boehringer Ingelheim, outside the submitted work;.
Conflict of interest: Dr. Spruit reports grants from Netherlands Lung Foundation, grants from Stichting Astma Bestrijding, grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, outside the submitted work.
- Received June 1, 2020.
- Accepted July 23, 2020.
- Copyright ©ERS 2020
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.